LRRK2 and Parkinson disease: Our study found that LRRK2 variant carriers exhibited less disease progression over time, particularly in terms of disability (for the p.G2385R and p.R1628P subgroups, as well as overall when these were combined with double-variant carriers), and in the global (total CISI-PD) scores for p.R1628P carriers.